Literature DB >> 10430414

A prospective study of preferences and actual treatment choices in ALS.

S M Albert1, P L Murphy, M L Del Bene, L P Rowland.   

Abstract

OBJECTIVE: To determine whether ALS patients' preferences for ameliorative or life-extending technologies elicited early in the disease were related to later treatment choices.
METHODS: In this prospective cohort study, 121 patients were seen at a tertiary ALS care center and followed for a median of 12 months. At baseline, patient preferences for use of tracheostomy and percutaneous endoscopic gastrostomy (PEG) placement were elicited. All patients received the same educational information before being interviewed about treatment preferences. Patients were then followed to determine if patients who viewed the interventions favorably at baseline were significantly more likely to use the interventions over follow-up.
RESULTS: Six to twelve percent of patients were certain they wanted tracheostomy and 28.2% wanted PEG. Preferences were related to later treatment choices: 20% of patients who found tracheostomy acceptable had one in the follow-up period, compared with 3.4% of those not in favor (p < 0.001). For PEG, similar findings were obtained: 48.5% who initially found it acceptable had PEG, versus 8.1% of those not in favor of this treatment (p < 0.001). Patients who found the interventions acceptable were more likely to be recently diagnosed, expressed greater attachment to life, and showed greater declines in pulmonary function over follow-up.
CONCLUSIONS: Patients with ALS were able to express their preferences for life-extending or ameliorative technologies and made choices consistent with these preferences. However, patient preferences may change over time, and clinical education efforts are required throughout the course of disease.

Entities:  

Mesh:

Year:  1999        PMID: 10430414     DOI: 10.1212/wnl.53.2.278

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Management of motor neurone disease.

Authors:  R S Howard; R W Orrell
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

2.  Persisting misconceptions about patients' attitudes at the end of life.

Authors:  Andreas S Lübbe
Journal:  Support Care Cancer       Date:  2005-01-12       Impact factor: 3.603

3.  Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients' perspectives.

Authors:  L P Greenaway; N H Martin; V Lawrence; A Janssen; A Al-Chalabi; P N Leigh; L H Goldstein
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

4.  What are cancer patients' preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff.

Authors:  S Sahm; R Will; G Hommel
Journal:  Support Care Cancer       Date:  2005-01-19       Impact factor: 3.603

5.  Experience matters: neurologists' perspectives on ALS patients' well-being.

Authors:  Helena E A Aho-Özhan; Sarah Böhm; Jürgen Keller; Johannes Dorst; Ingo Uttner; Albert C Ludolph; Dorothée Lulé
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

6.  Outcome of ventilatory support for acute respiratory failure in motor neurone disease.

Authors:  M D Bradley; R W Orrell; J Clarke; A C Davidson; A J Williams; D M Kullmann; N Hirsch; R S Howard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

7.  Family health care decision making and self-efficacy with patients with ALS at the end of life.

Authors:  Marie T Nolan; Joan Kub; Mark T Hughes; Peter B Terry; Alan B Astrow; Cynthia A Carbo; Richard E Thompson; Lora Clawson; Kenneth Texeira; Daniel P Sulmasy
Journal:  Palliat Support Care       Date:  2008-09

Review 8.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 9.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  Medical and supportive care among people with ALS in the months before death or tracheostomy.

Authors:  Steven M Albert; Adriene Whitaker; Judith G Rabkin; Maura del Bene; Toby Tider; Ita O'Sullivan; Hiroshi Mitsumoto
Journal:  J Pain Symptom Manage       Date:  2009-06-18       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.